和鉑醫藥-B(02142.HK)附屬諾納生物與科倫博泰簽署兩項補充協議
格隆匯12月23日丨和鉑醫藥-B(02142.HK)宣佈,公司全資子公司諾納生物(蘇州)有限公司(“諾納生物”)與四川科倫博泰生物醫藥股份有限公司(“科倫博泰”)簽署兩項補充協議(“補充協議”),其中諾納生物與科倫博泰一致同意科倫博泰有權就雙方共同開發的兩款ADC產品(產品1和產品2)許可給被許可第三方。補充協議應在科倫博泰與第三方之間的協議生效後生效。
根據補充協議,諾納生物有權獲得源於該兩款產品(產品1和產品2)所得款項的30%,具體包括:
產品1
● 產品1為諾納生物許可科倫博泰授權第三方項目,諾納生物有權獲得產品1首付款、里程碑付款和分級特許權使用費的30%;
● 產品1首付款為3000萬美元,諾納生物有權獲得其中的30%。
產品2
● 產品2為諾納生物許可科倫博泰與第三方合作開發項目;
● 諾納生物有權獲得產品2首付款、里程碑付款和分級特許權使用費的30%。
公吿顯示,諾納生物是一家全球化生物技術公司,致力於提供“Idea to IND”(“I to I™”)一站式解決方案(涵蓋通過臨牀前研究進行靶點認證及抗體發現)。利用Harbour Mice®平台的優勢及經驗豐富的治療性抗體發現團隊,提供涵蓋抗原製備、動物免疫、單B細胞篩選、抗體開發與工程、成藥性評估及藥理評估等多元化形態的一站式抗體及抗體相關發現服務。Harbour Mice®可生成經典雙輕鏈、雙重鏈(H2L2)形式及僅重鏈(HCAb)形式的全人源單克隆抗體。整合Harbour Mice®與單B細胞克隆平台,諾納生物聚焦助推全球變革性新一代藥物的發明。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.